Latest Bioscrip Inc (BIOS) Headlines Zacks Rank
Post# of 35
Posted On: 03/12/2014 6:36:20 PM
Latest Bioscrip Inc (BIOS) Headlines
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
BioScrip Now in Strong Sell Territory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 3:05PM CST
On Mar 4, 2014, Zacks Investment Research downgraded BioScrip to a Zacks Rank #5 (Strong Sell).
Weakness Seen in BioScrip (BIOS) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:36AM CST
BioScrip has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
BioScrip (BIOS) in Focus: Stock Tanks 12.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:47AM CST
BioScrip stock dropped 12.3% yesterday, falling below its one month volatile price range of $7.96 to $8.69
Downgrade Alert for BioScrip (BIOS)
Comtex SmarTrend(R) - Fri Feb 28, 7:03AM CST
BioScrip (NASDAQ:BIOS) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $7.40 on volume of 8.2 million shares, above average daily volume of 1.5 million. BioScrip, Inc. is a pharmacy benefit management and specialty pharmaceutical organization that partners with managed care organizations and healthcare providers to control prescription drug costs. The Company provides pharmacy benefit products and services and mail order pharmacy services, and is the fulfillment center for online retailers offering prescription and OTC products.
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 27, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why BioScrip Inc. Shares Stumbled
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 2:29PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BioScrip , a provider of home care...
BioScrip Reports Fourth Quarter 2013 Financial Results
PR Newswire - Wed Feb 26, 4:03PM CST
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 fourth quarter financial results. Fourth quarter revenue from continuing operations was $243.5 million and the net loss from continuing operations was $15.4 million, or $0.23 per basic and diluted share.
5 Stocks Ready to Explode on Bullish Earnings
at The Street - Mon Feb 24, 9:55AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
BioScrip Up 24.6% Since SmarTrend Uptrend Call (BIOS)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for BioScrip (NASDAQ:BIOS) on December 17th, 2013 at $6.97. In approximately 2 months, BioScrip has returned 24.62% as of today's recent price of $8.68.
IIROC Trading Resumption - SVL
CNW Group - Thu Feb 20, 7:21AM CST
Trading resumes in:
Blu® Homes Announces New Model and Updated 2014 Product Line, Emphasizing Spaciousness and Luxury Quality
PR Newswire - Wed Feb 19, 10:00AM CST
Blu® Homes, Inc. ("Blu"), America's leading provider of premium prefab homes, today announced the newest model in its 2014 product line, the Breeze Aire. This exciting new model offers a spacious layout, high-end finishes, and standard floor plan combinations that offer this beautiful home to clients across the United States in as little as seven months, as well as highly custom choices for those who prefer to make detailed engineering changes.
Healthcare Boom Brings This Sector ETF in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 9:00AM CST
With more people expected to have health insurance, this health care services ETF could benefit.
BioScrip Shares Up 18.4% Since SmarTrend's Buy Recommendation (BIOS)
Comtex SmarTrend(R) - Fri Feb 14, 5:07PM CST
SmarTrend identified an Uptrend for BioScrip (NASDAQ:BIOS) on December 17th, 2013 at $6.97. In approximately 2 months, BioScrip has returned 18.45% as of today's recent price of $8.25.
BioScrip to Host Fourth Quarter and Year-end 2013 Earnings Call
PR Newswire - Tue Feb 11, 4:00PM CST
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2013 fourth quarter and year-end financial results on Wednesday, February 26, 2014, after the market closes.
BioScrip Closes Private Placement of $200 Million of 8.875% Senior Notes due 2021
PR Newswire - Tue Feb 11, 3:30PM CST
BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip") today announced that it has completed its private placement of $200.0 million aggregate principal amount of 8.875% senior unsecured notes due 2021.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
BioScrip Now in Strong Sell Territory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 3:05PM CST
On Mar 4, 2014, Zacks Investment Research downgraded BioScrip to a Zacks Rank #5 (Strong Sell).
Weakness Seen in BioScrip (BIOS) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:36AM CST
BioScrip has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
BioScrip (BIOS) in Focus: Stock Tanks 12.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:47AM CST
BioScrip stock dropped 12.3% yesterday, falling below its one month volatile price range of $7.96 to $8.69
Downgrade Alert for BioScrip (BIOS)
Comtex SmarTrend(R) - Fri Feb 28, 7:03AM CST
BioScrip (NASDAQ:BIOS) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $7.40 on volume of 8.2 million shares, above average daily volume of 1.5 million. BioScrip, Inc. is a pharmacy benefit management and specialty pharmaceutical organization that partners with managed care organizations and healthcare providers to control prescription drug costs. The Company provides pharmacy benefit products and services and mail order pharmacy services, and is the fulfillment center for online retailers offering prescription and OTC products.
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 27, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why BioScrip Inc. Shares Stumbled
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 2:29PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BioScrip , a provider of home care...
BioScrip Reports Fourth Quarter 2013 Financial Results
PR Newswire - Wed Feb 26, 4:03PM CST
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 fourth quarter financial results. Fourth quarter revenue from continuing operations was $243.5 million and the net loss from continuing operations was $15.4 million, or $0.23 per basic and diluted share.
5 Stocks Ready to Explode on Bullish Earnings
at The Street - Mon Feb 24, 9:55AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
BioScrip Up 24.6% Since SmarTrend Uptrend Call (BIOS)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for BioScrip (NASDAQ:BIOS) on December 17th, 2013 at $6.97. In approximately 2 months, BioScrip has returned 24.62% as of today's recent price of $8.68.
IIROC Trading Resumption - SVL
CNW Group - Thu Feb 20, 7:21AM CST
Trading resumes in:
Blu® Homes Announces New Model and Updated 2014 Product Line, Emphasizing Spaciousness and Luxury Quality
PR Newswire - Wed Feb 19, 10:00AM CST
Blu® Homes, Inc. ("Blu"), America's leading provider of premium prefab homes, today announced the newest model in its 2014 product line, the Breeze Aire. This exciting new model offers a spacious layout, high-end finishes, and standard floor plan combinations that offer this beautiful home to clients across the United States in as little as seven months, as well as highly custom choices for those who prefer to make detailed engineering changes.
Healthcare Boom Brings This Sector ETF in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 9:00AM CST
With more people expected to have health insurance, this health care services ETF could benefit.
BioScrip Shares Up 18.4% Since SmarTrend's Buy Recommendation (BIOS)
Comtex SmarTrend(R) - Fri Feb 14, 5:07PM CST
SmarTrend identified an Uptrend for BioScrip (NASDAQ:BIOS) on December 17th, 2013 at $6.97. In approximately 2 months, BioScrip has returned 18.45% as of today's recent price of $8.25.
BioScrip to Host Fourth Quarter and Year-end 2013 Earnings Call
PR Newswire - Tue Feb 11, 4:00PM CST
BioScrip®, Inc. (NASDAQ: BIOS) announced today that the Company will release its 2013 fourth quarter and year-end financial results on Wednesday, February 26, 2014, after the market closes.
BioScrip Closes Private Placement of $200 Million of 8.875% Senior Notes due 2021
PR Newswire - Tue Feb 11, 3:30PM CST
BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip") today announced that it has completed its private placement of $200.0 million aggregate principal amount of 8.875% senior unsecured notes due 2021.
(0)
(0)